Cutaneous melanoma

This phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…

This early-stage trial tests whether injecting gold nanoparticles into tumors, followed by radiation and an immunotherapy drug, is safe for people with advanced melanoma. Only 6 participants will be enrolled. The goal is to check for side effects, not to see if the treatment work…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This study tests whether adding a fecal microbiota transplant called LND101 to standard immunotherapy can help stop advanced melanoma from growing or spreading. About 128 people with stage IV or unresectable melanoma will receive either immunotherapy alone or immunotherapy plus L…

This phase 2 trial compares two treatment combinations for people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a targeted therapy (encorafenib and binimetinib) plus an immunotherapy (nivolumab), while the other gets two immunotherapies (ipilimumab a…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This study tests two oral drugs, AMXT 1501 and DFMO, given alongside standard treatments for people with advanced solid tumors (breast cancer or melanoma) that have worsened after prior therapies. The goal is to find a safe dose and see if the combination helps shrink tumors or s…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This study tests whether one dose of the immunotherapy drug pembrolizumab, given before standard surgery, can shrink or eliminate tumors in people with stage IIb/c melanoma. About 30 adults with thick melanomas that haven't spread to lymph nodes will receive either pembrolizumab …

This trial tests AVT32-DRL_PB, a biosimilar (copy) of the cancer drug Keytruda, in 120 people with stage IIB/C or III melanoma whose tumors were fully removed. Half get the biosimilar, half get Keytruda, every 3 weeks. The main goal is to see if drug levels in the blood are simil…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This phase 2 trial tests whether adding an experimental immune-boosting pill (PRTX007) to standard immunotherapy (pembrolizumab) before surgery can improve outcomes for people with stage III melanoma. About 48 adults with resectable melanoma will take the combination for 9 weeks …

This Phase 3 trial tests a one-time cell therapy called IMA203 for people with advanced melanoma that has not responded to prior treatment. IMA203 is made from a patient's own immune cells and is designed to target cancer cells. The study compares IMA203 to standard treatments li…

This phase II trial is testing whether combining two drugs, binimetinib and imatinib, can shrink tumors in people with advanced KIT-mutant melanoma that cannot be removed by surgery. The study will enroll 25 participants with stage III or IV melanoma. The goal is to see how many …

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This early-stage study tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measu…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This early-phase trial is testing whether adding sitagliptin, a diabetes drug, to the immunotherapy pembrolizumab is safe and can help people with advanced kidney cancer or melanoma whose cancer has stopped responding to standard treatment. The study will first find the safest do…

This early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …

This phase 2 trial tests injecting two immunotherapy drugs (ipilimumab and nivolumab) directly into melanoma tumors before surgical removal. The goal is to shrink or eliminate the cancer while reducing the severe side effects that can occur when these drugs are given through a ve…

This early-phase trial tests a new combination treatment for people with advanced melanoma that has worsened despite standard immunotherapy. The treatment uses specially trained natural killer cells (either from the patient or a healthy donor) along with two immunotherapy drugs, …

This Phase 3 trial tests whether a genetically modified herpes virus (vusolimogene oderparepvec) combined with the immunotherapy drug nivolumab can help people with advanced melanoma that has stopped responding to prior treatments. About 400 participants will receive either the v…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This study is testing the drug pembrolizumab in Japanese children with solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell skin cancer. The main goals are to check the drug's safety, how the body processes it, and whether tumors shrink. About 20 participan…

This early-stage trial is testing whether injecting a flu vaccine directly into melanoma tumors can help shrink them. The study includes adults with stage I to IV melanoma who have at least one tumor that can be injected. The main goals are to find the safest dose and to see what…

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can stop advanced melanoma from growing or spreading. About 160 people with stage III or IV melanoma that cannot be removed by surgery will receive either the vaccine plus…

This early-phase study tests a new oral drug, RLY-8161, designed to block a specific cancer-driving protein called NRAS. It is for people with advanced melanoma or other solid tumors that have an NRAS mutation and have not responded to standard treatments. The main goals are to f…

This study tests whether removing only the largest affected lymph node (instead of all nearby lymph nodes) after 6 weeks of standard immunotherapy works just as well for stage III melanoma. About 1500 adults with stage IIIB-D melanoma will be randomly assigned to one of the two s…

This study tests a personalized treatment for advanced melanoma using a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), which are boosted with a protein called CD40L. After a short course of chemotherapy to make room, the enhanced cells are infused back a…

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.

This study tests a new drug, [212Pb]VMT01, that delivers a tiny dose of radiation directly to melanoma cells. It is being tested alone or with the immunotherapy nivolumab in 300 people with advanced melanoma that has worsened after prior treatment. The goal is to find safe doses …

This study tests a new treatment for people with stage IV melanoma that has spread to the brain. It combines a chemotherapy drug (temozolomide) with specially grown immune cells (NK cells) from a healthy donor. The goal is to see if this combination is safe and can shrink brain t…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This study is for people with high-risk melanoma who have tiny bits of tumor DNA still in their blood after surgery. It compares a two-drug immunotherapy combo against a single drug to see which better clears these hidden cancer cells. About 54 participants will be randomly assig…

This study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This study tests whether removing a smaller border of healthy tissue around a melanoma (narrow excision) works as well as the standard wider excision. About 1,000 adults with early-stage melanoma will be randomly assigned to one of the two surgeries. The goal is to see if narrow …

This study tests a new drug called LBL-024, alone or combined with LBL-007 or toripalimab, in 200 people with advanced melanoma. The goal is to see if these treatments are safe and can shrink tumors. Participants receive the drugs through an IV, and doctors monitor side effects a…

This phase 2 trial tests whether a combination of three drugs—fianlimab, cemiplimab, and ipilimumab—can safely shrink tumors in people with advanced melanoma that no longer responds to standard PD-1 therapy. The study enrolls 88 adults with locally advanced or metastatic melanoma…

This study is testing whether a low branched-chain amino acid (BCAA) diet, when combined with an immunotherapy drug (anti-PD-1), is safe and effective for people with stage III melanoma. About 80 participants will receive either the special diet or a normal diet alongside the imm…

This early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is …

This study tests whether adding an experimental drug (EIK1001) to standard immunotherapy (pembrolizumab) helps people with advanced melanoma live longer without their cancer growing. About 740 adults with stage 3 or 4 melanoma that cannot be removed by surgery will receive either…

This study tests a new drug, LNS8801, taken as a daily pill, either alone or with the immunotherapy pembrolizumab, in people with advanced melanoma that has not responded to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, …

This study tests whether people with melanoma can safely avoid a second surgery (re-excision) after the initial tumor is removed with clear margins. About 1,749 adults with stage pT1b to pT4b melanoma will be randomly assigned to either standard follow-up care including re-excisi…

This phase II trial is testing two oral drugs, binimetinib and encorafenib, in 35 adults with advanced melanoma that has spread to the brain. The drugs block enzymes that help cancer cells grow. The study aims to see if this combination can control the disease and improve surviva…

This early-phase study tests an injection of a modified herpes virus (RP1) directly into high-risk melanoma tumors. The goal is to see if it can kill cancer cells and reduce the chance of the cancer spreading to nearby lymph nodes. About 25 adults with thick or ulcerated melanoma…

This phase 2 trial tests the immunotherapy drug nivolumab (Opdivo) given before and after surgery for people with stage III or IV melanoma. The goal is to see if tailoring treatment based on tumor biomarkers leads to better outcomes. About 90 participants will be enrolled at a si…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

This study is testing whether giving one dose of the immunotherapy drug pembrolizumab six weeks before surgery can help the immune system fight high-risk melanoma more effectively. About 49 adults with melanoma that hasn't spread on scans will receive the drug, then have their ly…

This study tests whether adding a low-dose chemotherapy drug (cyclophosphamide) to an immunotherapy (pembrolizumab) can shrink tumors in people with advanced melanoma that has stopped responding to standard immunotherapy. About 14 adults with stage III or IV melanoma that cannot …

This large phase 3 trial is testing whether giving immunotherapy for 6 months after surgery for high-risk melanoma is as effective as the standard 12-month course. The study aims to enroll 1,792 adults who have had their melanoma surgically removed. If shorter treatment works, it…

This study tests an experimental drug called HMBD-501 in 180 adults with advanced solid tumors (melanoma, lung, or breast cancer) that have a protein called HER3 on their cells and have stopped responding to standard treatments. The trial has two phases: first, finding the safest…

This study tests whether giving new combinations of immunotherapy drugs before surgery can improve outcomes for people with advanced melanoma that is hard to treat. About 494 participants with stage 3 skin or mucosal melanoma will receive different drug combinations before their …

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…

This study tests whether adding a prebiotic-rich diet to standard immunotherapy before surgery can improve immune response in people with melanoma. About 35 adults with resectable melanoma will receive prebiotic snack packs and diet counseling alongside their usual treatment. The…

This early-stage trial is testing a treatment called X-PACT for people with advanced head and neck cancer, breast cancer, soft tissue sarcoma, or melanoma that has not responded to standard treatments. X-PACT involves injecting a drug called methoxsalen directly into the tumor an…

This early-phase trial tests a new treatment combining two experimental therapies (IMA203 and mRNA-4203) for people with advanced melanoma or synovial sarcoma that has not responded to prior treatments. The main goals are to check safety and find the best dose. About 15 participa…

This Phase 3 trial tests whether injecting Daromun directly into melanoma tumors before surgery can help prevent the cancer from returning. About 186 people with stage IIIB/C/D melanoma will either get Daromun injections plus standard surgery and follow-up therapy, or just surger…

This study tests two different immunotherapy treatments given before surgery for stage III melanoma that can be removed. One group gets a single drug (PD-1 blocker), the other gets a two-drug combo (PD-1 and CTLA-4 blockers). The combo may work better but also has more side effec…

This study tests two or three drugs (defactinib, avutometinib, and possibly encorafenib) in people with advanced melanoma that has spread to the brain. The goal is to see if these combinations can shrink brain tumors and how safe they are. About 33 adults whose melanoma worsened …

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma, lymphoma, or leukemia. Researchers will track side effects, cancer return, and overall health for years. The goal is to understand the long-term safety and effec…

This study tests an experimental treatment for adults with advanced melanoma who are already getting immunotherapy and planning surgery. The treatment combines focused ultrasound (using sound waves to heat and destroy tumor tissue) with an injection of a drug called polyICLC that…

This study tests whether giving standard immunotherapy drugs (ipilimumab and nivolumab) in the morning works better than giving them later in the day for people with advanced melanoma that has spread or cannot be removed. About 99 adults with stage IV melanoma will be randomly as…

This study tests whether a dietary supplement called Oral Impact® can lower the risk of severe side effects from immunotherapy drugs used to treat advanced melanoma. Twenty patients with inoperable locally advanced or metastatic melanoma will take the supplement for 35 days, star…

This early-phase trial tests whether adding two stress-blocking drugs—naltrexone and propranolol—to standard immunotherapy (ipilimumab and nivolumab) is safe for people with advanced melanoma. The study aims to find the best dose and check for side effects in 12 participants. If …

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

This study tests a new, non-invasive imaging device that uses red light to look at skin lesions. Researchers want to see if it can help doctors diagnose skin cancer without needing a biopsy. The study will enroll 10 adults with skin lesions at Emory University.

This study is testing whether an AI-powered smartphone app (NuvanaDx) can accurately detect skin cancer, including melanoma, by analyzing photos of suspicious moles or lesions. About 100 adults with concerning skin spots will take part. The goal is to see if the app can help catc…

Researchers are testing whether sulforaphane, a substance found in broccoli and other cruciferous vegetables, can prevent melanoma in people who have multiple atypical moles and a prior history of melanoma. Participants take sulforaphane or a placebo by mouth. The trial measures …

This study compares two surgical techniques—perforator flap versus skin graft—for repairing the wound left after removing a stage II melanoma. Researchers want to see which method leads to faster wound healing and better quality of life. Forty adults with melanoma on the trunk, a…

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study tests whether EMLA numbing cream can reduce pain from Technetium 99 injections used in lymphoscintigraphy, a standard mapping procedure for skin cancers like melanoma. About 100 adults with skin cancer will receive either EMLA cream or a placebo before the injection. T…

This study tests whether a single dose of NPX-5 (a psilocybin drug) combined with talk therapy can reduce severe anxiety in people who have trouble adjusting to a cancer diagnosis. About 87 adults aged 18–80 with moderate-to-severe anxiety will receive one of three doses (25 mg, …

This study tests a short self-help booklet designed for people recently diagnosed with certain cancers (breast, colorectal, gynecological, melanoma, or bladder) who still smoke. The goal is to see if the booklet is easy to use and helps increase their motivation to quit. About 10…

This study looks at whether using genetic markers from a child's skin tumor can help doctors decide how much surgery is needed. About 51 children and young adults up to age 25 with localized melanoma or similar growths will have their tumor tissue reviewed centrally. Based on ris…

This study tests whether a digital tool called MySmartSkin can help melanoma survivors do better skin self-exams. About 385 survivors will use either the enhanced app or a standard educational webpage. The goal is to see if the app leads to more thorough skin checks and earlier d…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or g…

This study observes patients with high-risk stage II melanoma to see if starting anti-PD-1 immunotherapy before surgery leads to better outcomes compared to the usual timing after surgery. Researchers will track when patients begin systemic therapy and compare results between the…

This study from Mayo Clinic is looking at how T cells (a type of immune cell) change during anti-PD-1 immunotherapy in people with advanced melanoma, lung cancer, or other solid tumors. Researchers will collect blood and tissue samples from 500 participants to measure specific ma…

This study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…

This study is creating a large collection of blood and tissue samples from people with skin cancer and healthy volunteers. Researchers will store these samples and medical data to support future studies on skin cancer. The goal is to provide a valuable resource for translational …

This study looks at how melanoma tumors process energy, specifically glucose, to see if certain metabolic patterns are linked to cancer spread. Researchers will give a special glucose tracer to 400 adults with melanoma before their surgery and analyze the tumor tissue. Participan…

This study enrolls 200 people with acral or cutaneous melanoma who are starting standard immunotherapy. Researchers will collect blood samples every 3 weeks and tumor tissue after about 3 months of treatment. By analyzing circulating tumor cells, DNA, and other markers, they aim …

This study looks at how lifestyle factors like diet, exercise, mental health, and social support affect quality of life and outcomes in people with melanoma. Researchers will follow 5,000 participants over time using surveys and medical records. The goal is to gather knowledge th…

This study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…

This study looks at how electrochemotherapy—a treatment that uses electric pulses to help chemotherapy drugs enter cancer cells—changes the environment around melanoma skin tumors. Researchers will collect tissue samples from 150 adults before and after treatment to see how immun…

This study looks at 24 people with advanced melanoma who are starting immunotherapy. Researchers will do a special PET/CT scan and a blood test for tumor DNA about 3-4 weeks after the first treatment. The goal is to see if these early tests can predict whether the immunotherapy i…

This study is investigating why some melanomas stop responding to immunotherapy. Researchers will take biopsies from 20 patients with advanced melanoma before and after treatment to see how tumor metabolism changes. The goal is to understand resistance mechanisms and find new way…

This observational study is looking at 25 adults aged 18 to 39 who have been diagnosed with melanoma. Researchers want to find out how common melanoma is in this age group and identify risk factors, skin features, and genetic changes linked to the disease. The goal is to better u…

This observational study in Italy will examine the link between work-related sun exposure and melanoma. Researchers will interview 300 people (120 with melanoma, 180 without) about their job history, sun habits, and protection use. The goal is to better understand how outdoor wor…

This study looks at how two different drug combinations affect the immune system in people with advanced melanoma that cannot be removed by surgery. Researchers will compare Opdualag (nivolumab/relatlimab) with cemiplimab/fianlimab by analyzing blood and tumor samples from 20 par…

This study follows 300 adults with advanced melanoma who are receiving immune checkpoint inhibitors. Researchers will collect blood samples, quality-of-life surveys, and medical records to track symptoms over time. The goal is to identify patterns and risk factors for worse sympt…

This study looks at whether beta-glucan, a natural fiber from yeast, can improve the immune response to the immunotherapy drug pembrolizumab in people with stage III or IV melanoma. Researchers will measure changes in immune cells from blood samples. The goal is to understand how…

This study tests whether eating dried chicory root (a high-fiber prebiotic) every day for 6 weeks can change gut bacteria and immune cells in 20 people who had surgery for stage II melanoma. Researchers want to see if it increases helpful substances called short-chain fatty acids…